insights_auto
Waarom is FARN gedaald 4,11%?
Meer informatiechevron_right
FARN:LON
Faron Pharmaceuticals Oy
GBX 35,00
arrow_downward
-4,11%(-1,50) 1D
9 okt, 16:30:00 GMT+1 · GBX
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor FARN genereren…
Openen
GBX 35,00
Hoog
GBX 38,00
Laag
GBX 35,00
Beursw.
73,96 mln.
Gem. vol.
45,22K
Volume
15,60K
52 wk hoog
GBX 193,58
52 wk laag
GBX 34,00
WPA
GBX -0,10
Uitstaande aandelen
31,03 mln.
Aantal medewerkers
36
Openen
GBX 35,00
Hoog
GBX 38,00
Laag
GBX 35,00
Beursw.
73,96 mln.
Gem. vol.
45,22K
Volume
15,60K
52 wk hoog
GBX 193,58
52 wk laag
GBX 34,00
WPA
GBX -0,10
Uitstaande aandelen
31,03 mln.
Aantal medewerkers
36
Nieuwsartikelen
Van webbronnen en nieuwspartners
Invezz
·
1 dag geleden
Dow stijgt 423 punten terwijl tech-aandelen herstellen, telecoms dalen door SpaceX
BeInCrypto
·
2 uur geleden
Pokémon-kaarten verslaan Bitcoin, goud en de S&P 500 met 150% rendement
Invezz
·
3 dagen geleden
Dow opent 120 punten lager door stijgende olieprijs en hogere Treasury-yields
MarketScreener Nederland
·
1 dag geleden
Nasdaq stijgt voor vierde wekelijkse winst op rij; olieprijzen stabiliseren
Profiel
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Over Faron Pharmaceuticals Oy